CMR FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gardner, T. B.
Right arrow Articles by Hill, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gardner, T. B.
Right arrow Articles by Hill, D. R.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 2001, p. 114-128, Vol. 14, No. 1
0893-8512/01/$04.00+0   DOI: 10.1128/CMR.14.1.114-128.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Treatment of Giardiasis

Timothy B. Gardner and David R. Hill*

Division of Infectious Diseases, University of Connecticut Health Center, Farmington, Connecticut

Giardia lamblia is both the most common intestinal parasite in the United States and a frequent cause of diarrheal illness throughout the world. In spite of its recognition as an important human pathogen, there have been relatively few agents used in therapy. This paper discusses each class of drugs used in treatment, along with their mechanism of action, in vitro and clinical efficacy, and side effects and contraindications. Recommendations are made for the preferred treatment in different clinical situations. The greatest clinical experience is with the nitroimidazole drugs, i.e., metronidazole, tinidazole, and ornidazole, which are highly effective. A 5- to 7-day course of metronidazole can be expected to cure over 90% of individuals, and a single dose of tinidazole or ornidazole will cure a similar number. Quinacrine, which is no longer produced in the United States, has excellent efficacy but may be poorly tolerated, especially in children. Furazolidone is an effective alternative but must be administered four times a day for 7 to 10 days. Paromomycin may be used during early pregnancy, because it is not systematically absorbed, but it is not always effective. Patients who have resistant infection can usually be cured by a prolonged course of treatment with a combination of a nitroimidazole with quinacrine.

* Corresponding author. Mailing address: Division of Infectious Diseases, University of Connecticut Health Center, Farmington, CT 06030-3212. Phone: (860) 679-4700. Fax: (860) 679-4701. E-mail: dhill{at}exchange.uchc.edu.

Clinical Microbiology Reviews, January 2001, p. 114-128, Vol. 14, No. 1
0893-8512/01/$04.00+0   DOI: 10.1128/CMR.14.1.114-128.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Vaccine Immunol.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.